Elena Ongaro

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 514 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer

Chiara Cremolini, Carlotta Antoniotti, Alexander Stein et al. · Journal of Clinical Oncology · 2020 · 236 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research

Filippo Pietrantonio, M. Caporale, Federica Morano et al. · International Journal of Cancer · 2016 · 149 citations · Full text

Medicine, Cancer Biology, Oncology +13

Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer

Francesco Graziano, Annamaria Ruzzo, Elisa Giacomini et al. · The Pharmacogenomics Journal · 2016 · 117 citations

Life Sciences, Molecular Biology, Oncology +17

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study

Filippo Pietrantonio, Giovanni Fucà, Federica Morano et al. · Clinical Cancer Research · 2017 · 109 citations · Full text

Medicine, Molecular Medicine, Oncology +17